On October 29, the Amgen Tour of California announced that the race would not continue for the 2020 season. The organizers referred to it as a hiatus—indicating there’s a chance it’ll return at a later date. Bob Stapleton, the chairman of USA Cycling, expressed hope that the race would make a return in the future.
On behalf of USA Cycling, I would like to thank AEG, Kristin and her team for providing an outstanding showcase for the sport in America and for our American athletes, Stapleton said in a press release. We stand ready to help rally additional support and resources in the hopes of resuming this event in 2021.
Introduced in 2006, the Amgen Tour of California had a 14-year-long run. The stage race was the only one at the UCI WorldTour level held in the United States, for both men and women. The men’s race consisted of seven stages, and the women’s race—known as the Amgen Tour of California Women’s Race empowered with SRAM—consisted of three stages. It also offered equal prize money for the men and women, starting in 2018.
The race was also noteworthy because its schedule overlapped with that of the Giro d’Italia, in mid-May, prompting teams and cyclists to strategically choose between the two. This has been a very difficult decision to make, but the business fundamentals of the Amgen Tour of California have changed since we launched the race 14 years ago, said Kristin Klein, president of the Amgen Tour of California and executive vice president of AEG Sports, in a press release.
While professional cycling globally continues to grow and we are very proud of the work we have done to increase the relevance of professional cycling, particularly in the United States, it has become more challenging each year to mount the race. This new reality has forced us to re-evaluate our options, and we are actively assessing every aspect of our event to determine if there is a business model that will allow us to successfully relaunch the race in 2021, Klein stated.